What is Medix Infusion?
Medix Infusion specializes in providing comprehensive infusion therapies, disease management programs, and specialized pharmacy services. The company is dedicated to serving patients with chronic and acute illnesses, particularly within underserved communities. Their operational resilience, highlighted by their 'No Pause Button!' message during the COVID-19 pandemic, demonstrates a commitment to continuous patient care and access to essential medical treatments.
How much funding has Medix Infusion raised?
Medix Infusion has raised a total of $35M across 1 funding round:
Series B
$35M
Series B (2023): $35M with participation from Noro-Moseley Partners and Echo Health Ventures
Key Investors in Medix Infusion
Noro-Moseley Partners
Noro-Moseley Partners is a venture capital firm that specializes in early growth equity investments for rapidly-scaling B2B software and healthcare companies. They focus on partnering with exceptional CEOs to scale high-growth businesses, offering strategic guidance and support beyond capital.
Echo Health Ventures
Echo Health Ventures is a strategic venture capital firm focused on investing in and growing innovative healthcare companies. They partner with organizations committed to transforming healthcare delivery through original solutions and sustainable impact, aiming to drive systemic healthcare transformation.
What's next for Medix Infusion?
The recent major strategic investment positions Medix Infusion for substantial growth and operational scaling. This capital infusion is expected to fuel the expansion of their service footprint, potentially enabling them to reach more underserved populations and broaden their therapeutic offerings. The company's focus on chronic disease management and infusion pharmacy services, coupled with strategic backing, suggests a trajectory towards becoming a leading provider in its niche, driving innovation in patient care delivery.
See full Medix Infusion company page
